Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Sep 17;31(12):1717–1729. doi: 10.1038/s41418-024-01379-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a IL-1β release from C57B6/J, C57B6/N, Nlrp3⁻^/⁻ (Nlrp3^tm1Tsch) and Nlrp3⁻^/− (Nlrp3^tm1Bhk) BMDMs stimulated with LPS (10 ng/ml) and Talabostat (0.3, 3 or 30 μM) for 24 h (C57B6/J, n = 3, C57B6/N, Nlrp3^tm1Tsch and Nlrp3^tm1Bhk, n = 4). b LDH release relative to total lysis controls from C57B6/J, C57B6/N, Nlrp3⁻^/− (Nlrp3^tm1Tsch) and Nlrp3⁻^/− (Nlrp3^tm1Bhk) BMDMs stimulated with LPS (10 ng/ml) and Talabostat (0.3, 3 or 30 μM) for 24 h (C57B6/J, n = 3, C57B6/N, Nlrp3^tm1Tsch and Nlrp3^tm1Bhk, n = 4). c IL-1β release from C57B6/J, C57B6/N, Nlrp3⁻^/− (Nlrp3^tm1Tsch) and Nlrp3⁻^/− (Nlrp3^tm1Bhk) BMDMs primed with LPS (10 ng/ml) for 3 h and then stimulated with Nigericin (8 μM) for 90 min (n = 4). d Heatmap of log₂ LFQ values of NLRP3, NLRP1B and NLRP1A proteins from C57B6/J, C57B6/N, Nlrp3⁻^/− (Nlrp3^tm1Tsch) and Nlrp3⁻^/⁻ (Nlrp3^tm1Bhk) BMDMs stimulated with LPS (10 ng/ml) for 24 h (n = 4). Grey spaces indicate samples where proteins were not detected (ND). e LDH release, relative to total lysis controls, from C57B6/J and 129S2 BMDMs after stimulation with Talabostat (0.3 or 3 μM) for 24 h (n = 3). f Heatmap of log₂ LFQ values of NLRP3, NLRP1B and NLRP1A proteins from C57B6/J and 129S2 BMDMs. Grey spaces indicate samples where proteins were not detected (ND). g Western blot analysis of C-terminal HA tagged NLRP1A, NLRP1B^129S and NLRP1B^C57B6 expression in HEK ASC-GFP cells. h Bar plot showing % of ASC speck positive HEK ASC-GFP cells empty or either stably expressing NLRP1A, NLRP1B^129S or NLRP1B^C57B6 stimulated with Talabostat (0.3, 3 or 30 μM) for 16 h (NLRP1A, NLRP1B^129S, NLRP1B^C57B6: n = 3, Empty: n = 1). a–h P values were calculated using multiple unpaired parametric t-tests. FDR (q) was calculated using Benjamini–Hochberg correction. *q < 0.05, **q < 0.01, ***q < 0.001, ****q < 0.0001, ns not significant (q > 0.05). Error bars represent standard deviation.